AFMD News and Press, Affimed N.V. From 04/12/21

AFM24 induces strong tumor cell killing independent of KRAS mutations AFM24, in combination with adoptive NK cells, leads to dose-dependent tumor regression Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology compa...

Could These Biotech Stocks Be The Best Stocks To Invest In Right Now? You can’t deny that biotech stocks have and continue to receive a whole lot of attention from investors now. Accordingly, this is because of the current pandemic where biotech companies are continuously...

Shares of drugmaker Affimed (NASDAQ: AFMD) are up 19% at 2:06 p.m. EDT after the company disclosed positive data from an early-stage clinical trial of its innate cell engager AFM13 in patients with Hodgkin's lymphoma. The data release only included results from the first four pa...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Affimed N.V Announces Positive Initial Clinical Data ” Affimed N.V. (NASDAQ: AFMD) surged over 30% in premarket trading after the co...

Gainers: Celcuity (CELC) +43%.NCS Multistage (NCSM) +39%.MEDIROM Healthcare Technologies (MRM) +31%.Natuzzi (NTZ) +24%.Affimed (AFMD) +23%.Tenax Therapeutics (TENX) +23%.Brooklyn ImmunoTherapeutics (BTX) +20%.GT Biopharma (GTBP) +16%.Sohu.com (SOHU) +15%.fuboTV (...

Shares of Affimed N.V. (NASDAQ:AFMD) traded today at $10.69, eclipsing its 52-week high. Approximately 7.2 million shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares. Affimed N.V. share prices have moved between a 52-week high of $10.69 and a 5...

Gainers: Celcuity (CELC) +56%, GeoVax Labs (GOVX) +36%, Affimed (AFMD) +24%, Tenax Therapeutics (TENX) +22%, Genetic Technologies (GENE) +13%.Losers: Novo Integrated Sciences (NVOS) -24%, Provention Bio (PRVB) -21%, Virpax ...

Celcuity (CELC) +55% on licensing agreement up to $340M for breast cancer treatment gedatolisib.Affimed N.V. (AFMD) +29% on positive data from NK cells + AFM13 in solid tumors.Greenwich LifeSciences (GLSI) +29% on robust immune response Phase IIb data in breast cancer.Gulf Reso...

Affimed (AFMD) announces positive initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed’s innate cell engager AFM13 (CD16A/CD30) in adult patients with recurrent/refractory CD30-positive lymphomas...

All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100% There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-v...